Intervention not reported
Primary outcome 1: participant‐ or parent‐rated symptoms of eczema (SCORAD part C) at the end of active treatment Visual analogue scale for itch and sleep disturbance ranging from 0 to 10 for each symptom and combined ranging from 0 to 20. The hig... · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
1 finding from 1 review
Recovery timea from second twitch (T2) to train‐of‐four ratio (TOFR) > 0.9 (moderate block) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
1 finding from 1 review
Recovery timea from second twitch (T2) to train‐of‐four ratio (TOFR) > 0.9 (moderate block) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recovery timea from second twitch (T2) to train‐of‐four ratio (TOFR) > 0.9 (moderate block) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse reaction due to the skin care product or procedure, e.g. skin irritation, rash, itching, allergic reaction · adults with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse reaction due to the skin care product or procedure, e.g. skin irritation, rash, itching, allergic reaction · adults with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse reaction due to the skin care product or procedure, e.g. skin irritation, rash, itching, allergic reaction · adults with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse reaction due to the skin care product or procedure, e.g. skin irritation, rash, itching, allergic reaction · adults with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects ‐ itching · people with atopic dermatitis
Tacrolimus 0.03% showed no clear difference in adverse effects ‐ itching compared with pimecrolimus 1% (low certainty).
1 finding from 1 review
Itching VAS (Analysis 1.2) Participant's rating. Scale from 1 to 10 · atopic eczema
1 finding from 1 review
Itching VAS (Analysis 1.2) Participant's rating. Scale from 1 to 10 · atopic eczema
1 finding from 1 review
Itching VAS (Analysis 1.2) Participant's rating. Scale from 1 to 10 · atopic eczema
1 finding from 1 review
Life skills: No important change kitchen skills Royal Edinburgh Occupational Therapy Assessment Form · patients with chronic mental illnesses
1 finding from 1 review
Intervention not reported
Change in allergic rhinitis daily symptom score during the grass pollen season Each daily symptom score was the summation of (i) runny nose score, (ii) itchy nose score and (iii) sneezing score (each of these scores self recorded on a severity sca... · patients with allergic rhinitis1
1 finding from 1 review
Itchy/Gritty eyes Symptom scores · patients with allergic conjunctivitis
1 finding from 1 review
Clinically significant response on global state · non response in schizophrenia
It is very uncertain whether increasing the antipsychotic dose changes global state: Clinically relevant response – as defined by trial… compared with switching the antipsychotic drug (very low certainty).
1 finding from 1 review
Leaving the study early ‐ due to adverse effects (short term) · non response in schizophrenia
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · non response in schizophrenia
1 finding from 1 review
Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · non response in schizophrenia
1 finding from 1 review
Risk for at least one adverse event per patient · non response in schizophrenia
1 finding from 1 review